Dimerix Limited Share Price

DXB

AU000000DXB7

Biotechnology & Medical Research

Market Closed - Australian S.E. 05:10:11 30/10/2026 GMT			5-day change	1st Jan Change
0.2100 ^AUD	-2.33%		+7.69%	-61.82%

10-23	Dimerix Says Independent Data Supports Investigational Therapy for Kidney Disease; Shares Down 5%	MT
10-19	Dimerix Chair to Retire	MT

Analysts' recommendations: Dimerix Limited

07-17	Dimerix Hits 'Major Milestone' With AU$10 Million Financing Package, Euroz Hartleys Says	MT
06-17	Dimerix's Everest Deal Adds Value, Eases Funding Concerns, Euroz Hartleys Says	MT
05-01	Dimerix's Potential Non-Dilutive Funding May Lead to Ongoing Phase Three Trial Being Fully Funded, Euroz Hartleys Says	MT
04-14	Dimerix Poised to Benefit From US FDA's Approval of Travere Therapeutics' Kidney Disorder Drug, Euroz Hartleys Says	MT
04-08	Dimerix Sees No Impact From US Pharma Tariffs, Says Euroz Hartleys	MT

More recommendations

Press Releases: Dimerix Limited

07-17	Mission Therapeutics strikes deal worth up to $292 million for Dimerix Ltd to develop Acute Kidney Injury asset MTX652, sharpens focus on its CNS pipeline	AQ
06-17	Everest Medicines Enters into Exclusive Licensing Agreement with Dimerix for DMX-200 in Greater China, South Korea and Southeast Asia	AQ
01/05/25	Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States	AQ
05/10/23	ADVANZ PHARMA and Dimerix enter into an Exclusive License Agreement to commercialise DMX-200 in Europe, Canada, Australia, and New Zealand	AQ
26/07/22	Dimerix : Quarterly Appendix 4C and Activities Report	PU

More press releases

Managers and Directors: Dimerix Limited

Manager	Title	Age	Since
Nina Webster CEO	Chief Executive Officer	-	26/08/2018
Michael Tonroe DFI	Director of Finance/CFO	59	28/01/2026
David Fuller CTO	Chief Tech/Sci/R&D Officer	-	30/09/2023

Director	Title	Age	Since
Sonia Maria Poli BRD	Director/Board Member	61	02/07/2015
Hugh Alsop CHM	Chairman	-	-
Nina Webster BRD	Director/Board Member	-	26/08/2018

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DIMERIX LIMITED	-2.33%	+7.69%	-58.82%	+16.67%	88.7M
WUXI APPTEC CO., LTD.	-0.62%	-1.87%	+42.87%	+64.15%	63.77B
ARGENX SE	+0.35%	+3.20%	+14.40%	+81.76%	56.37B
LONZA GROUP AG	+0.53%	+1.96%	+16.24%	+103.35%	54.62B
IQVIA HOLDINGS INC.	-2.81%	-4.31%	+23.50%	+47.83%	44.06B
BEONE MEDICINES AG	-0.33%	-1.93%	+19.28%	+98.80%	42.11B
REVOLUTION MEDICINES, INC.	+0.55%	+2.31%	+225.14%	+866.21%	41B
GENMAB A/S	+3.27%	+47.96%	+112.84%	+96.58%	34.92B
CELLTRION, INC.	+1.22%	-1.44%	+14.57%	+46.95%	32.82B
INSMED INCORPORATED	+0.89%	+20.55%	-40.62%	+349.24%	24.7B
Average	+0.07%	+7.55%	+36.94%	+177.16%	39.44B
Weighted average by Cap.	+0.18%	+5.44%	+47.97%	+176.63%

See all sector performances

Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company focused on developing new therapies for kidney diseases. The Company's lead program, DMX-200, is in Phase III clinical development for focal segmental glomerulosclerosis (FSGS), a serious and life-threatening rare kidney disease with limited treatment options. In addition, it is advancing a Phase II program in acute kidney injury (AKI), further strengthening its pipeline in high-need renal indications. DMX-200 is a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker, the standard of care treatment for hypertension and kidney disease. The Company's DMX-652 is a selective inhibitor of USP30 - a mitochondrial enzyme that slows the removal of damaged mitochondria. The Phase II trial is designed to investigate DMX-652's potential to prevent kidney injury and preserve renal function. It is also developing DMX-700 for respiratory disease.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
30/10/26	A$0.2100	-2.33%	333,872
29/10/26	A$0.2150	+4.88%	462,081
28/10/26	A$0.2050	+2.50%	736,782
27/10/26	A$0.2000	-.--%	178,868
26/10/26	A$0.2000	+2.56%	33,422

Delayed Quote Australian S.E.

More quotes

Market Cap	126M 88.7M 79.44M 73.07M 66.21M 124M 8.42B 871M 350M 4.43B 333M 326M 13.97B	P/E 2025	-24.3x	P/E 2026	-4.13x
Enterprise Value	110M 77.5M 69.41M 63.85M 57.85M 108M 7.36B 761M 306M 3.87B 291M 285M 12.21B	EV / Sales 2025	49.4x	EV / Sales 2026	16.9x
Free-Float	77.77%	Yield 2025 *	-	Yield 2026	-

10-23	Dimerix Says Independent Data Supports Investigational Therapy for Kidney Disease; Shares Down 5%	MT
10-19	Dimerix Chair to Retire	MT
10-18	Dimerix Limited Announces Board Changes, Effective October 30, 2026	CI
10-16	Dimerix Says First 100 Patients Enrolled in Phase 3 Kidney Disease Clinical Trial Complete Two-Year Double-Blind Treatment Period	MT
10-05	Dimerix Says First Patient Completes Four Years in Clinical Program for Kidney Disease Drug Candidate; Shares Rise 7%	MT
09-23	Dimerix Receives AU$17 Million in Proceeds After Completing Initial Drawdown Under Non-Dilutive Funding Facility	MT
09-21	Dimerix Limited(ASX:DXB) dropped from S&P/ASX All Ordinaries Index	CI
09-14	Dimerix Says Mexican Composition of Matter Patent Granted for Drug Candidate	MT
09-04	Dimerix Reaches Major Milestone With AU$34 Million Non-Dilutive Loan Facility, Euroz Hartleys Says	MT
09-04	Dimerix Secures AU$34 Million in Non-Dilutive Loan Facility Agreements; Shares Up 4%	MT
08-27	Dimerix Limited Reports Earnings Results for the Full Year Ended June 30, 2026	CI
08-20	Dimerix Receives Initial $10 Million Upfront Payment Under Everest Medicines License Deal; Shares Gain 4%	MT
08-17	Dimerix Completes Transfer of Acute Kidney Injury Drug Candidate's US Investigational New Drug Application, Shares Up 6%	MT

1 day	-2.33%
1 week	+7.69%
1 month	-8.70%
3 months	-14.29%
6 months	-8.70%
Current year	-61.82%

1 week	0.2	0.22
1 month	0.2	0.24
Current year	0.16	0.56
1 year	0.16	0.66
3 years	0.13	0.78
5 years	0.05	0.78
10 years	0.05	0.78

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/12/25	Mark Diamond	Free	Chairman	100,000	0.0167%
12/12/25	Mark Diamond	Free	Chairman	100,000	0.0167%
12/12/25	Sonia Maria Poli	Free	Director	100,000	0.0167%

Dimerix Limited Share Price

Stocks

DXB

AU000000DXB7

Biotechnology & Medical Research

Valuation: Dimerix Limited

Chart: Dimerix Limited

Latest news: Dimerix Limited

Analysts' recommendations: Dimerix Limited

Press Releases: Dimerix Limited

Quotes and Performance

Price Extremes

Managers and Directors: Dimerix Limited

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

	2025	2026
Net sales	5.59M 3.93M 3.52M 3.24M 2.93M 5.48M 373M 38.61M 15.5M 196M 14.75M 14.44M 619M	6.35M 4.47M 4M 3.68M 3.34M 6.24M 424M 43.92M 17.63M 223M 16.78M 16.42M 704M
Net income	-13.25M -9.32M -8.35M -7.68M -6.96M -13.01M -885M -91.59M -36.77M -466M -34.99M -34.24M -1.47B	-29.81M -20.97M -18.78M -17.28M -15.66M -29.27M -1.99B -206M -82.72M -1.05B -78.72M -77.04M -3.3B
Net Debt	-68.19M -47.97M -42.96M -39.52M -35.81M -66.93M -4.55B -471M -189M -2.4B -180M -176M -7.56B	-15.92M -11.2M -10.03M -9.23M -8.36M -15.63M -1.06B -110M -44.18M -559M -42.04M -41.14M -1.76B